Within 90 minutes of a single intranasal dose, Semax measurably alters the expression of hundreds of genes in the rodent hippocampus — including a rapid and robust upregulation of brain-derived neurotrophic factor (BDNF). That a seven-amino-acid fragment of adrenocorticotropic hormone, stripped of its endocrine activity, could so directly engage the brain’s neurotrophic machinery is one of the more remarkable findings to emerge from Soviet-era peptide chemistry. Decades later, Semax remains on the Russian Register of Medicines for stroke, cognitive disorders, and optic nerve atrophy — but its mechanisms are only now being fully characterized in Western literature.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to the 4-7 fragment of adrenocorticotropic hormone (ACTH) with a C-terminal Pro-Gly-Pro extension that confers proteolytic stability. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences and Lomonosov Moscow State University, and approved in Russia in the 1990s as an intranasal formulation for cerebrovascular and cognitive indications.[1]
The Pro-Gly-Pro tripeptide tail is critical: it dramatically extends half-life in biological fluids compared to native ACTH(4-7), while the parent heptapeptide retains the neurotropic activity of ACTH without its corticosteroid-releasing effects. This separation of behavioral and endocrine activity was first demonstrated by De Wied and colleagues in the 1970s, who showed that ACTH fragments could influence learning and memory independent of adrenal stimulation.[1]
How Semax Works
BDNF and NGF Upregulation: The most well-characterized effect of Semax is rapid induction of neurotrophin expression. In the basal forebrain and hippocampus of rats, a single intranasal dose increases BDNF and nerve growth factor (NGF) mRNA and protein within hours, with downstream activation of TrkB signaling — the canonical pathway through which BDNF promotes synaptic plasticity, dendritic arborization, and neuronal survival.[2]
Melanocortin Receptor Engagement: As an ACTH fragment, Semax interacts with melanocortin receptors (notably MC4R) expressed throughout the central nervous system. Melanocortin signaling modulates attention, arousal, and stress adaptation, providing a plausible link between the peptide’s structural lineage and its observed nootropic effects.[1]
Enkephalinase Inhibition: Semax inhibits the degradation of endogenous regulatory peptides, including enkephalins, by suppressing enkephalin-degrading enzymes in the blood. Prolonged enkephalin signaling contributes to its anxiolytic and analgesic profile and may partly explain its stress-buffering effects.[3]
Dopaminergic and Serotonergic Modulation: Animal studies show that Semax alters monoamine turnover in the striatum and prefrontal cortex, increasing dopamine and serotonin metabolism in regions relevant to attention and executive function.[3]
Transcriptomic Reprogramming: Microarray studies of the rat hippocampus after a single Semax dose reveal differential expression of hundreds of genes involved in immune response, vascular tone, and neuronal plasticity — suggesting that the peptide functions less as a classical receptor agonist and more as a broad regulator of stress- and plasticity-related transcription programs.[4]
The Pharmacokinetic Case for Intranasal Delivery
Semax is administered as nasal drops because peptides of its size are poorly absorbed orally and degrade rapidly in plasma. Intranasal delivery exploits two routes simultaneously: systemic absorption through the highly vascular respiratory mucosa, and direct nose-to-brain transport along olfactory and trigeminal nerve pathways, which bypass the blood-brain barrier entirely.
Pharmacokinetic studies using radiolabeled Semax show that detectable concentrations appear in the brain within minutes of intranasal administration, with preferential accumulation in the olfactory bulb, hypothalamus, and hippocampus. The peptide’s plasma half-life is short — on the order of minutes — but its central effects persist for hours, consistent with rapid receptor engagement followed by sustained downstream transcriptional changes.[2] This kinetic profile is the principal reason injectable formulations have never been developed: the nasal route delivers the peptide directly to the tissues where it acts.
Clinical and Preclinical Evidence
Ischemic Stroke: The largest body of clinical data on Semax concerns acute ischemic stroke, where it is used adjunctively in Russian neurology practice. Russian clinical trials have reported improved neurological recovery and reduced infarct progression when Semax is administered in the acute and subacute phases, though these studies have not been replicated in Western multicenter trials.[1]
Cognitive and Attentional Effects: In healthy volunteers and patients with mild cognitive impairment, Semax has been reported to improve sustained attention, working memory, and operator performance under fatigue. The effect size is modest but consistent across small studies, and is mechanistically consistent with BDNF-mediated enhancement of hippocampal and prefrontal plasticity.[1]
Neurotrophin Induction in Vivo: Dolotov and colleagues demonstrated that intranasal Semax produces a sustained increase in BDNF expression in the rat basal forebrain — a region critical for cholinergic tone and attentional control. The same group showed activation of TrkB signaling downstream of BDNF induction, confirming functional engagement of the neurotrophin pathway.[2]
Optic Nerve and Retinal Protection: Semax is registered in Russia for optic nerve atrophy, an indication grounded in animal models showing protection of retinal ganglion cells under ischemic and excitotoxic stress — effects also attributable to BDNF upregulation, since BDNF is a primary survival factor for these neurons.[1]
Stress Resilience: In rodent models of immobilization and chronic mild stress, Semax attenuates corticosterone elevation, normalizes monoamine turnover, and prevents stress-induced deficits in spatial memory. These effects are blocked by inhibitors of BDNF/TrkB signaling, implicating neurotrophin induction as the proximate mechanism.[3]
Safety Profile
Semax has been used clinically in Russia for over two decades with a generally favorable safety profile. Reported adverse effects are uncommon and largely limited to local nasal irritation at higher doses. Because the molecule is a short peptide that does not engage glucocorticoid release despite its ACTH lineage, it does not produce the endocrine side effects associated with ACTH itself.
The principal limitations of the safety record are the sparse long-term data outside of Russian clinical practice, the absence of large-scale randomized Western trials, and limited characterization of effects during pregnancy and lactation. Theoretical concerns about chronic BDNF upregulation — including potential effects on pain sensitization, mood instability, and proliferation in BDNF-responsive tissues — have not been systematically evaluated in long-duration studies.
Semax vs Other Cognitive Peptides and Nootropics
Semax vs Selank: Selank, also developed at the Institute of Molecular Genetics, is a synthetic analog of the immunomodulatory peptide tuftsin and is primarily anxiolytic, acting via GABAergic and enkephalinergic pathways. Semax overlaps in its enkephalinase-inhibiting activity but is more strongly cognitive and neurotrophic, while Selank is more strongly anxiolytic. The two are sometimes used sequentially or in combination in Russian practice.[3]
Semax vs Cerebrolysin: Cerebrolysin is a porcine brain-derived peptide mixture also used in stroke and dementia. It contains BDNF-mimetic and CNTF-mimetic fragments and is administered parenterally. Semax differs in being a single defined synthetic peptide with a characterized sequence, simpler pharmacology, and non-invasive administration.
Semax vs Direct BDNF Approaches: Recombinant BDNF itself has failed as a therapeutic because it does not cross the blood-brain barrier and has a very short half-life. Small-molecule TrkB agonists such as 7,8-dihydroxyflavone offer one alternative; Semax offers another, by inducing endogenous BDNF transcription rather than supplying or mimicking the protein directly. The endogenous induction strategy preserves the spatial and temporal control of physiological BDNF release.[2]
Semax vs Classical Nootropics: Compared with racetams, modafinil, or cholinesterase inhibitors, Semax operates upstream — at the level of neurotrophic and transcriptional control — rather than through acute neurotransmitter modulation. This makes its acute subjective effects subtler than stimulants but potentially more durable, with cognitive benefits that persist beyond the dosing window.
References
- Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. “Design and investigation of an ACTH(4-10) analog lacking D-amino acids and hydrophobic radicals.” Neuroscience and Behavioral Physiology. 1995;25(3):234-240.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry. 2006;97 Suppl 1:82-86.
- Eremin KO, Kudrin VS, Saransaari P, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228.
- Shadrina MI, Dolotov OV, Grivennikov IA, et al. “Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.” Neuroscience Letters. 2001;308(2):115-118.
